Patents by Inventor David P. Rotella

David P. Rotella has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7384958
    Abstract: Compounds of the formula (I) are useful as inhibitors of cGMP PDE especially Type 5.
    Type: Grant
    Filed: March 1, 2007
    Date of Patent: June 10, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yingzhi Bi, Guixue Yu, David P. Rotella, John E. Macor
  • Patent number: 7378430
    Abstract: Compounds of the formula (I) are useful as inhibitors of cGMP PDE especially Type 5.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: May 27, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yingzhi Bi, Guixue Yu, David P. Rotella, John E. Macor
  • Patent number: 7265145
    Abstract: Compounds are provided which are antagonists of the calcium sensing receptor, and have the general formula wherein m is 0, 1, 2, 3 or 4; each X is independently selected from the group consisting of hydrogen, halo, cyano, nitro, OCF3, hydroxy, amino, carboxyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, haloalkyl, alkoxy, alkoxycarbonylalkyl, hydroxycarbonylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkylalkyl, R1O, R1R2N, R1OCO, R1CO, R1R2NCO, R1R2NCONR2a, R1OCONR2a, R1CONR2a, R1S, R1SO, R1SO2, R1R2NSO2, R1R2NSO2NR2a, and R1SO2NR2a; R1 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; R2 and R2a are the same or different and are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloheteroalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; n is 1, 2, or 3; W is O or H,R3; R3 is hydrogen or hydroxyl; Ar is a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl g
    Type: Grant
    Filed: May 26, 2004
    Date of Patent: September 4, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: John K. Dickson, R. Michael Lawrence, Jacques Y. Roberge, David P. Rotella, Wu Yang
  • Patent number: 7173042
    Abstract: Compounds of the formula (I) are useful as inhibitors of cGMP PDE especially Type 5.
    Type: Grant
    Filed: December 21, 2004
    Date of Patent: February 6, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yingzhi Bi, Guixue Yu, David P. Rotella, John E. Macor
  • Patent number: 7105537
    Abstract: The present invention relates to modulators of the calcium sensing receptor having the formula I wherein Ar1, X, n, R1, R2, R3 and Q are as defined herein.
    Type: Grant
    Filed: January 27, 2004
    Date of Patent: September 12, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashvinikumar V. Gavai, Roy J. Vaz, John K. Dickson, Jr., Jacques Y. Roberge, Wu Yang, Timur Gungor, James R. Corte, David P. Rotella, Yufeng Wang
  • Patent number: 6835737
    Abstract: Compounds of the formula (I) are useful as inhibitors of cGMP PDE especially Type 5.
    Type: Grant
    Filed: April 14, 2003
    Date of Patent: December 28, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yingzhi Bi, Guixue Yu, David P. Rotella, John E. Macor
  • Publication number: 20040259860
    Abstract: Compounds are provided which are antagonists of the calcium sensing receptor, and have the general formula 1
    Type: Application
    Filed: May 26, 2004
    Publication date: December 23, 2004
    Inventors: John K. Dickson, R. Michael Lawrence, Jacques Y. Roberge, David P. Rotella, Wu Yang
  • Publication number: 20040229860
    Abstract: The present invention relates to modulators of the calcium sensing receptor having the formula I 1
    Type: Application
    Filed: January 27, 2004
    Publication date: November 18, 2004
    Inventors: Ashvinikumar V. Gavai, Roy J. Vaz, John K. Dickson, Jacques Y. Roberge, Wu Yang, Timur Gungor, James R. Corte, David P. Rotella, Yufeng Wang
  • Publication number: 20030225128
    Abstract: Compounds of the formula (I) 1
    Type: Application
    Filed: April 14, 2003
    Publication date: December 4, 2003
    Inventors: Yingzhi Bi, Guixue Yu, David P. Rotella, John E. Macor
  • Patent number: 6576644
    Abstract: Compounds of the formula (I) are useful as inhibitors of cGMP PDE especially Type 5.
    Type: Grant
    Filed: August 20, 2001
    Date of Patent: June 10, 2003
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Yingzhi Bi, Guixue Yu, David P. Rotella, John E. Macor
  • Publication number: 20020177587
    Abstract: 1
    Type: Application
    Filed: August 20, 2001
    Publication date: November 28, 2002
    Inventors: Yingzhi Bi, Guixue Yu, David P. Rotella, John E. Macor
  • Patent number: 6087368
    Abstract: Novel quinazolinone compounds, methods of using such compounds in the treatment of cGMP-associated conditions such as erectile dysfunction, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: May 28, 1999
    Date of Patent: July 11, 2000
    Assignee: Bristol-Myers Squibb Company
    Inventors: John E. Macor, David P. Rotella, Harold N. Weller, III, David W. Cushman, Joseph P. Yevich
  • Patent number: 5516772
    Abstract: Disclosed are derivatives of the indolocarbazole alkaloid K-252a of the Formulae I-VI, useful for enhancing neurotrophin-induced activity of neurotrophin responsive cells. A particularly preferred neurotrophin is NT-3, and a particularly preferred neurotrophin responsive cell is one which comprises a trk receptor. The enhanced neurotrophin-induced activity occasioned by the disclosed K-252a derivatives may be determined by the following assays: ChAT activity; DRG neuronal survival; or cell division (mitogenesis).
    Type: Grant
    Filed: September 16, 1994
    Date of Patent: May 14, 1996
    Assignees: Cephalon, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Marcie A. Glicksman, Robert L. Hudkins, David P. Rotella, Nicola T. Neff, Chikara Murakata
  • Patent number: 5468872
    Abstract: Functional K-252a derivatives are used to enhance trk phosphorylation and to potentiate the activity of neurotrophin-3 (NT-3). These compounds can be used to treat neurological disorders, alone or in combination with NT-3.
    Type: Grant
    Filed: September 16, 1993
    Date of Patent: November 21, 1995
    Assignees: Cephalon, Inc., Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Marcie A. Glicksman, David P. Rotella, Nicola Neff, Chikara Murakata
  • Patent number: 5336796
    Abstract: One aspect of the present invention relates to a process of making cyclohexane-1,2-di(O)-4,5-di(N) diastereomers which are useful as a synthons for various diastereoisomeric pharmaceutical systems. The present invention also relates to the stereoisomer compounds which are derived from retro- synthetic analysis. In another aspect, the present invention relates to novel antineoplasic Pt(II) complexes derived from the stereoisomers and the processes for making such Pt(II) complexes. Mono- and di-hydroxyl substitution on the cyclohexane ring renders the organoplatinum complex relatively more water soluble, thereby facilitating intravenous administration. The Pt(II) complexes of the present invention are less nephrotoxic than cisplatin and are readily excreted via the kidney due to their enhanced water solubility.
    Type: Grant
    Filed: April 16, 1993
    Date of Patent: August 9, 1994
    Assignee: Ohio State University
    Inventors: Donald T. Witiak, David P. Rotella
  • Patent number: 5206400
    Abstract: One aspect of the present invention relates to a process of making cyclohexane-1,2-di(O)-4,5-di(N) diastereomers which are useful as a synthons for various diastereoisomeric pharmaceutical systems. The present invention also relates to the stereoisomer compounds which are derived from retro-synthetic analysis. In another aspect, the present invention relates to novel antineoplastic Pt(II) complexes derived from the stereoisomers and the processes for making such Pt(II) complexes. Mono- and di-hydroxyl substitution on the cyclohexane ring renders the organoplatinum complex relatively more water soluble, thereby facilitating intravenous administration. The Pt(II) complexes of the present invention are less nephrotoxic than cisplatin and are readily excreted via the kidney due to their enhanced water solubility.
    Type: Grant
    Filed: July 7, 1986
    Date of Patent: April 27, 1993
    Assignee: Ohio State University
    Inventors: Donald T. Witiak, David P. Rotella